600422 KPC Pharmaceuticals, Inc.

Watchlist

14.43
+0.08+0.56%

Market Closed Jun 25 15:00 CST

10.92BMarket Cap17.99P/E (TTM)

About KPC Pharmaceuticals, Inc. Company

The company was founded in March 1951 and listed on the Shanghai Stock Exchange in December 2000. The company has deep professional pharmaceutical experience. Relying on Yunnan's rich plant resources, Kunyao Group has successively developed more than 40 new natural medicine products with advanced standards at home and abroad, including the three major series of artemisia, 37, and Tianma, as well as traditional Chinese medicine and ethnic medicine. At the same time, it inherits fine Chinese medicines, focuses on the 37 industrial chain, and is committed to providing high-quality product services and system solutions for chronic disease management and aging health. The company's industry is pharmaceutical manufacturing. Its business area covers the entire pharmaceutical industry chain, and its core business covers fields such as drug research and development, production and sales, pharmaceutical distribution, and the health industry. The company's core products include Kunyao Hemocalcitone series, artemisinyl ether series, Kunming Traditional Chinese Medicine Shenling Spleen and Stomach Granules, Hepatic Soothing Granules, Incense Stomach Calciferol softgels, sodium hyaluronate injections, etc. The company was selected as the “National Technological Innovation Demonstration Enterprise” assessed by the Ministry of Industry and Information Technology, the “2019 China Pharmaceutical Innovation Enterprise Top 100”, “Top 500 Chinese Enterprise Patents”, and “2022 Chinese Pharmacy Staff Recommendation Rate Brand”, ranked 13th in the “2022 Top 100 Proprietary Chinese Medicine Companies List” and ranked 12th in the “2022 Top 30 Chinese Medicine Listed Companies”. It won the “2023 Best Practice Case for Listed Company Directors” by the China Association of Listed Companies, Securities Daily Honors include the “ESG Pioneer Practitioner” honor, the “Social Responsibility (S) Pioneer Enterprise Award” issued by the Financial Federation and the China Environmental Protection Federation, and the top 100 enterprises in the national pharmaceutical manufacturing industry.

Company Profile

Short Name-A昆药集团

Symbol-A600422

Company NameKPC Pharmaceuticals, Inc.

Listing DateDec 6, 2000

Issue Price10.22

Shares Offered40.00M share(s)

FoundedDec 14, 1995

Listed ExchangeSH Stock Exchange

Legal Representativewei yan

General Managerwei yan

Secretarymengxun zhang

Accounting FirmKPMG Huazhen Certified Public Accountants (Special General Partnership)

Securities Representativeyu dong

Legal CounselBeijing Deheng (Kunming) Law Firm

Employees1126

Phone0871-68324311

Office AddressNo. 166, Medical Road, National High-tech Industrial Development Zone, Kunming, Yunnan

Zip Code650106

Registered AddressNo. 166, Medical Road, National High-tech Industrial Development Zone, Kunming, Yunnan

Fax0871-68324267

Emailirm.kpc@kpc.com.cn

Websitehttp://www.kpc.com.cn

Business License530000000014415

BusinessProcurement, production and sales of Chinese and Western medicinal raw materials, chemical raw materials, intermediates, reagents, packaging materials, extracts, Chinese medicine tablets, agricultural and sideline products and Chinese herbal medicines (cultivation, acquisition and sale), industrial hemp cultivation, R&D, flower and leaf processing, domestic trade, material supply and marketing, import and export business of goods and technology, technological development, consulting services, mechanical processing, pharmaceutical equipment manufacturing, installation and maintenance business, pharmaceutical engineering design, medical device management, foreign aid materials projects.

Company Executives

Name
Position
Salary

wenduo wu
Chairman, Directors, Nomination Committee Members, Chairman of the Strategy and ESG Committee
--

hongshen li
Vice Chairman, Directors, Strategy and ESG Committee Member
--

wei yan
Vice Chairman, Directors, President, Strategy and ESG Committee Member
2.62M

hui zhou
Directors, Strategy and ESG Committee Member
--

zheng liang
Directors, Member of the Audit and Risk Control Committee
--

ting guo
Directors, Member of the Remuneration and Assessment Committee
--

zhi yang
Independent Directors, Chairman of the Remuneration and Assessment Committee, Strategy and ESG Committee Member
100.00K

guihua wang
Independent Directors, Chairman of the Nomination Committee, Member of the Audit and Risk Control Committee
--

jinguo xin
Independent Directors, Nomination Committee Members, Member of the Remuneration and Assessment Committee, Chairman of the Audit and Risk Control Committee
100.00K

mengxun zhang
Board Secretary, VP, General Counsel
1.44M

yu dong
Securities Affairs Representative
--

jiang zhong
Chairman of the Supervisory Board, Auditors
--

kang deng
Auditors
--

jinfeng shao
Auditors
--

junfeng liu
Senior Vice President
2.32M

cheng sun
VP
1.24M

lichun li
VP
--

ming he
VP
--

tong gao
VP
1.91M

li meng
Executive Vice President
1.89M

zhiqiang sun
Chief Financial Officer
1.62M

wensen zhang
Employee Supervisors
326.80K

linxi li
Employee Supervisors
470.80K

The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals. Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index. This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content. Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios. The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals. Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index. This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content. Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios.

No. Symbol 5D % Chg

ProShares Short VIX Short-Term Futures ETF

SVXY